Reaction
Renal Tubular Atrophy reporting signals
As of the last recalculation, Renal Tubular Atrophy appears in 863 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 165.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 74 | 165.9 | 166.9 |
| Tacrolimus Ointment 0.1% | 271 | 76.1 | 76.2 |
| Tacrolimus Extended-Release Capsules | 271 | 75.8 | 76.0 |
| Tacrolimus | 307 | 72.8 | 73.0 |
| Mycophenolic Acid | 78 | 64.5 | 64.7 |
| Anti-Thymocyte Globulin (Rabbit) | 21 | 64.3 | 64.5 |
| Sirolimus | 34 | 63.3 | 63.5 |
| Mycophenolate Mofetil | 250 | 62.1 | 62.2 |
| Mycophenolate Mofetil Hydrochloride | 250 | 62.0 | 62.1 |
| Mycophenilic Acid | 44 | 53.9 | 54.0 |
| Everolimus Tablets | 35 | 52.4 | 52.5 |
| Valganciclovir Hydrochloride Powder, | 21 | 42.5 | 42.6 |
| Valganciclovir | 26 | 34.3 | 34.3 |
| Valganciclovir Hydrochloride | 26 | 34.3 | 34.3 |
| Ganciclovir | 10 | 23.8 | 23.9 |
| Cyclosporine | 97 | 23.6 | 23.6 |
| Ganciclovir Sodium | 10 | 23.0 | 23.1 |
| Entecavir | 10 | 20.9 | 20.9 |
| Everolimus | 37 | 18.3 | 18.3 |
| Calcitriol Capsules 0.25 Mcg | 14 | 17.1 | 17.1 |
| Calcitriol Capsules 0.5 Mcg | 14 | 17.1 | 17.1 |
| Calcitriol | 14 | 16.9 | 16.9 |
| Orlistat | 13 | 12.3 | 12.3 |